213 related articles for article (PubMed ID: 38255993)
1. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
3. Bulk and single-cell transcriptome reveal the immuno-prognostic subtypes and tumour microenvironment heterogeneity in HCC.
Ji D; Lu S; Zhang H; Li Z; Wang S; Miao T; Jiang Z; Ao L
Liver Int; 2024 Apr; 44(4):979-995. PubMed ID: 38293784
[TBL] [Abstract][Full Text] [Related]
4. Establishment and Validation of a Novel Risk Score for Hepatocellular Carcinoma Based on Bile Acid and Bile Salt Metabolism-Related Genes.
Shi Q; Yuan X; Xue C; Gu X; Li L
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239939
[TBL] [Abstract][Full Text] [Related]
5. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
7. Identification of copper metabolism and cuproptosis-related subtypes for predicting prognosis tumor microenvironment and drug candidates in hepatocellular carcinoma.
Liu X; Sun B; Yao Y; Lai L; Wang X; Xiong J; Zhang X; Jiang J
Front Immunol; 2022; 13():996308. PubMed ID: 36275743
[TBL] [Abstract][Full Text] [Related]
8. Characterizing ligand-receptor interactions and unveiling the pro-tumorigenic role of CCL16-CCR1 axis in the microenvironment of hepatocellular carcinoma.
Dai Z; Wang Y; Sun N; Zhang C
Front Immunol; 2023; 14():1299953. PubMed ID: 38274805
[TBL] [Abstract][Full Text] [Related]
9. Identification and analysis of necroptosis-associated signatures for prognostic and immune microenvironment evaluation in hepatocellular carcinoma.
Lu J; Yu C; Bao Q; Zhang X; Wang J
Front Immunol; 2022; 13():973649. PubMed ID: 36081504
[TBL] [Abstract][Full Text] [Related]
10. Metabolism-associated molecular classification of hepatocellular carcinoma.
Yang C; Huang X; Liu Z; Qin W; Wang C
Mol Oncol; 2020 Apr; 14(4):896-913. PubMed ID: 31955511
[TBL] [Abstract][Full Text] [Related]
11. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
12. The m
Ma E; Li J; Shen C; Gu Y; Zhang X; Li L; Zhao J; Wang Z
Front Immunol; 2023; 14():1227593. PubMed ID: 37691948
[TBL] [Abstract][Full Text] [Related]
13. Signature construction and molecular subtype identification based on liver-specific genes for prediction of prognosis, immune activity, and anti-cancer drug sensitivity in hepatocellular carcinoma.
Zhang X; Xiao Z; Zhang X; Li N; Sun T; Zhang J; Kang C; Fan S; Dai L; Liu X
Cancer Cell Int; 2024 Feb; 24(1):78. PubMed ID: 38374122
[TBL] [Abstract][Full Text] [Related]
14. Development of Prognostic Features of Hepatocellular Carcinoma Based on Metabolic Gene Classification and Immune and Oxidative Stress Characteristic Analysis.
Cui S; Zhang M; Bai S; Bi Y; Cong S; Jin S; Li S; He H; Zhang J
Oxid Med Cell Longev; 2023; 2023():1847700. PubMed ID: 36860731
[TBL] [Abstract][Full Text] [Related]
15. NK cell marker gene-based model shows good predictive ability in prognosis and response to immunotherapies in hepatocellular carcinoma.
Li J; Li Y; Li F; Xu L
Sci Rep; 2023 May; 13(1):7294. PubMed ID: 37147523
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive characterization of β-alanine metabolism-related genes in HCC identified a novel prognostic signature related to clinical outcomes.
Jia Y; Chen X; Guo H; Zhang B; Liu B
Aging (Albany NY); 2024 Apr; 16(8):7073-7100. PubMed ID: 38637116
[TBL] [Abstract][Full Text] [Related]
17. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
18. Glycosylation-related molecular subtypes and risk score of hepatocellular carcinoma: Novel insights to clinical decision-making.
Shi Y; Wang Y; Yang R; Zhang W; Zhang Y; Feng K; Lv Q; Niu K; Chen J; Li L; Zhang Y
Front Endocrinol (Lausanne); 2022; 13():1090324. PubMed ID: 36605944
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma.
Liu L; Liu Z; Gao J; Liu X; Weng S; Guo C; Hu B; Wang Z; Zhang J; Shi J; Guo W; Zhang S
Front Immunol; 2022; 13():964190. PubMed ID: 35967384
[TBL] [Abstract][Full Text] [Related]
20. Identification and Characterization of Robust Hepatocellular Carcinoma Prognostic Subtypes Based on an Integrative Metabolite-Protein Interaction Network.
Chen D; Zhang Y; Wang W; Chen H; Ling T; Yang R; Wang Y; Duan C; Liu Y; Guo X; Fang L; Liu W; Liu X; Liu J; Otkur W; Qi H; Liu X; Xia T; Liu HX; Piao HL
Adv Sci (Weinh); 2021 Sep; 8(17):e2100311. PubMed ID: 34247449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
